![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 7, 4585-4588, February 15, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§ and
From the
Medical Research Council Immunochemistry
Unit, Department of Biochemistry, University of Oxford, Oxford
OX1 3QU, United Kingdom and ¶ Department of Medicinal Chemistry,
University of Utah, Salt Lake City, Utah 84112-5820
The ubiquitous glycosaminoglycan
(GAG)1 hyaluronan has diverse
biological roles in vertebrates. These include acting as a vital structural component of connective tissues, the formation of loose hydrated matrices that allow cells to divide and migrate
(e.g. during development), immune cell adhesion and
activation, and a role in intracellular signaling (1-3). This wide
range of activities may seem surprising for an unbranched
polysaccharide comprised entirely of a repeating disaccharide,
D-glucuronic
acid( Many hyaladherins contain a common structural domain of ~100
amino acids in length, termed a Link module, that is involved in ligand
binding (4). However, a growing number of hyaladherins lack this domain
and are unrelated to each other at the primary sequence level. Fig.
1 shows the domain organization of the
Link module superfamily and other hyaluronan-binding proteins.
![]()
INTRODUCTION
TOP
INTRODUCTION
The Hyaladherins: Hyaluronan-...
The Structures of Hyaluronan-...
Toward Understanding the...
Regulation of Hyaluronan-...
Summary
REFERENCES
1
3)N-acetyl-D-glucosamine(
1
4), which (unlike other GAGs) is neither attached to a protein core nor
O- or N-sulfated. Such diversity results in fact
from the large number of hyaluronan-binding proteins (often termed
hyaladherins) that exhibit significant differences in their tissue
expression, cellular localization, specificity, affinity, and
regulation. Therefore, characterization of the molecular basis of
hyaluronan recognition by proteins and how this is modulated in
vivo is an important key to understanding the biology of this GAG.
In this article, we review the structural organization of vertebrate
hyaladherins and how this may contribute to their different biological activities.
![]()
The Hyaladherins: Hyaluronan-binding Proteins
TOP
INTRODUCTION
The Hyaladherins: Hyaluronan-...
The Structures of Hyaluronan-...
Toward Understanding the...
Regulation of Hyaluronan-...
Summary
REFERENCES

View larger version (33K):
[in a new window]
Fig. 1.
The modular organization of the
hyaladherins.
The Link Module Superfamily-- The Link module (also referred to as a proteoglycan tandem repeat (5)) was first identified in the link protein isolated from cartilage. The link protein is comprised of an immunoglobulin domain and two contiguous Link modules, and this molecular arrangement is also found in the G1 domains of aggrecan, versican, neurocan, and brevican (Fig. 1). These proteoglycans form huge, link protein-stabilized complexes with hyaluronan that provide the load-bearing function in articular cartilage, give elasticity to blood vessels, and contribute to the structural integrity of many tissues such as skin and brain (6, 7). A brain-specific link protein (BRAL1) has been characterized recently (8), which may be part of a larger link protein gene family (9).
The ubiquitous hyaluronan receptor CD44 has diverse functions including the attachment, organization, and turnover of extracellular matrix at the cell surface and mediates the migration of lymphocytes during inflammation (10). CD44 can exist in numerous isoforms because of alternative splicing of 10 variant exons in different combinations. Each isoform contains a single Link module close to the N terminus of the protein. The hyaluronan binding properties of CD44 are determined by the isoform and the cell type on which it is expressed (11).
Apart from CD44, the only other member of the Link module superfamily that has been clearly identified as a hyaluronan receptor is LYVE-1. This recently discovered molecule is restricted in its expression to lymph vessel endothelium and appears to be involved in hyaluronan degradation (12).
The protein product of tumor necrosis factor-stimulated gene-6 (TSG-6) that contains a single Link module is secreted in response to inflammatory stimuli, e.g. in the articular joints of arthritis patients (13, 14). TSG-6 has been implicated in the regulation of leukocyte migration, and the pattern of its expression suggests that it is likely to be involved in extracellular matrix remodeling. Although the role of TSG-6 is, at present, poorly understood, its hyaluronan binding properties (and their structural basis) are probably the best characterized of any hyaladherin.
Fig. 1 shows several new members of the Link module superfamily (i.e. Stabilin-1, CAB61358, and KIA0527), all of which contain a single Link module. Stabilin-1 (accession code AJ275213) is a transmembrane protein that was initially identified as a partial sequence (KIA0246) cloned from a myeloid cell line (15). Stabilin-1 and CAB61358 may be identical to the proteins designated WF-HABP and BM-HABP (16), for which only the amino acid sequences for the Link modules have been reported. These both show about 50% identity with the Link module of TSG-6. However, it is unclear whether they bind hyaluronan as no functional data are yet available. The same is true for KIA0527 that was cloned from brain tissue (17).
Non-Link Module Hyaladherins--
Inter-
-inhibitor (I
I), a
serine protease inhibitor plentiful in serum, was one of the first
proteins found to associate with hyaluronan (18). As shown in Fig. 1
I
I is an unusual proteoglycan with a chondroitin-4-sulfate chain
linked to bikunin (containing two Kunitz inhibitor domains) and two
heavy chains (HC1 and HC2) attached to the GAG by ester bonds via their
C-terminal aspartic acid residues (19). I
I is essential during
ovulation, acting to stabilize the hyaluronan-rich cumulus
extracellular matrix with which it forms a covalent complex (20, 21).
The covalent association links the C-terminal ends of HC1 and HC2 to
the C6-hydroxyl of an internal N-acetylglucosamine of
hyaluronan via an ester bond, while the bikunin chain is released (20).
It has also been reported that I
I can bind non-covalently to
hyaluronan (22), as is the case for all other hyaluronan-protein
interactions, but the precise regions of the molecule involved have not
been determined.
CD38, a type II membrane glycoprotein, has been reported to be a hyaladherin (23). This protein is an enzyme with NADase activity, and this property has been studied much more extensively than its hyaluronan binding function for which no biological role has yet been ascribed (24).
Plasma hyaluronan-binding protein (25) is a serine protease that may be involved in wound healing, where high levels of hyaluronan accumulate (26). It is comprised of epidermal growth factor modules, a kringle domain, and a serine protease domain. However, there is no information on which of these are involved in ligand binding.
Recently two related hyaladherins, IMP-150 and SPACRCAN, have been isolated from human retina. IMP-150, which may be identical to SPACR (27), is expressed by cone and rod photoreceptor cells and is present in the interphotoreceptor matrix (28). SPACRCAN (a chondroitin sulfate proteoglycan) is likely to be a receptor on photoreceptors and pinealocytes (29). SPACR and SPACRCAN both contain two SEA modules, a structural domain often associated with O-glycosylation (30). The positions of the hyaluronan-binding sites on these proteins are not yet established.
The receptor for hyaluronan-mediated motility (RHAMM) mediates cell migration and proliferation in normal and tumor cells (reviewed in Ref. 2). A number of RHAMM isoforms are present in the cytoplasm and nucleus and are also transiently expressed on the surface of activated leukocytes and subconfluent fibroblasts.
The presence of hyaladherins inside cells is not surprising given the
increasing evidence for intracellular hyaluronan (1). In fact, there
are three hyaluronan-binding proteins, in addition to RHAMM, which have
been found in intracellular locations to date. The first is a
vertebrate homologue of yeast and Drosophila CDC37 (31),
which may be involved in cell cycle and kinase function as it
associates with RAF and pp60v-src (32). The second
protein, P-32 (also known as HABP-1), was originally co-purified with
pre-mRNA splicing factor SF2 (33) and subsequently shown to be a
hyaluronan-binding protein (34). P-32 is likely to have a role in
cellular signal transduction (35) and may be involved in
nucleus-mitochondrion interactions (36). As with RHAMM, P-32 can also
be detected on the surface of some cells, e.g. transformed
fibroblasts. The third protein, IHABP4, was identified using the same
monoclonal antibody that permitted isolation of vertebrate CDC37 (37)
and has been detected in the cytoplasm of IHABP4-transfected cells. Its
role in hyaluronan trafficking or intracellular signaling remains to be determined.
| |
The Structures of Hyaluronan-binding Domains |
|---|
|
|
|---|
The Link module structure (5), which has defined the "consensus
fold" for the entire Link module superfamily, consists of two
-helices and two triple-stranded anti-parallel
-sheets (Fig.
2). The single Link module from TSG-6 is
sufficient for high affinity interaction with hyaluronan (38). In
contrast, CD44 has a hyaluronan-binding domain of ~160 amino acids
comprised of a Link module with N- and C-terminal extensions that are
essential for folding and functional activity (39, 40). An even larger domain is utilized by the link protein, aggrecan, and aggrecan-related proteoglycans, as these all have a pair of contiguous Link modules in
their hyaluronan-binding regions. In link protein and aggrecan both
Link modules are involved in binding (6, 41). Therefore, hyaluronan-binding domains from Link module-containing proteins can be
divided into three subgroups (Types A, B, and C) on the basis of size
(Fig. 3). The size of the binding domain
appears to correlate broadly with the length of hyaluronan recognized. For instance, hexasaccharides (HA6) and decasaccharides
(HA10) are the minimum sizes of hyaluronan required for
high affinity interaction with Type A and Type C domains, respectively
(38). Hyaluronan binding to CD44 can be displaced by either
HA6 or HA10, depending on the cell background
on which it is expressed (42). A recent study indicates that
HA10 is the smallest oligosaccharide that binds optimally
to cell surface CD44 in a monovalent fashion, whereas an increase in
binding avidity is seen with oligomers (
HA20) that can
interact with two CD44 molecules simultaneously (43).
|
|
The amino acids of CD44 involved in the interaction with hyaluronan have been determined by site-directed mutagenesis (39, 44). Functionally important residues are present both on the Link module (Fig. 3) and on the flanking sequences indicating that a large coherent binding site is likely to be formed (i.e. the extensions may constitute a subdomain in intimate contact with the Link module (4)). Recently, amino acids in TSG-6 that are perturbed on interaction with hyaluronan have been identified (38), and mutagenesis has allowed residues directly involved in binding to be distinguished from those affected due to ligand-induced conformation changes (45). These studies show that in Link module-containing proteins, binding residues are brought together from different parts of the sequence and that a folded structure is necessary to generate a ligand-binding surface. It should be noted that linear sequences (so called BX7B motifs (46); see below) do not appear to be involved in Link module-hyaluronan interactions (38).
The hyaluronan-binding sites in TSG-6 and CD44 have similar locations on the Link module, suggesting that the position of the ligand interaction surface may be conserved across the superfamily (45). However, there appear to be some major differences in the details of the residues (and sequence positions) involved in mediating binding in the two proteins. In fact, comparisons of the Link module sequences of CD44 and TSG-6 with all the other members of the superfamily indicate that the molecular details of hyaluronan binding (i.e. the interaction networks) are likely to be distinct in each protein. This is perhaps not surprising given the different subtypes of hyaluronan-binding domains (described above) as well as many other differences in specificity and regulation. For example TSG-6 binds to chondroitin-4-sulfate with high affinity, but this GAG is not recognized by aggrecan or link protein (47).
The structure of a P-32 homotrimer, which is likely to be its
oligomeric state in physiological solutions, has been solved by x-ray
crystallography (36). Each monomer consists of seven consecutive
-strands that form a highly twisted antiparallel
-sheet flanked
by one N-terminal and two C-terminal
-helices. The position of the
hyaluronan-binding site has not yet been established.
The hyaluronan-binding domain of RHAMM has been localized to a 62-amino acid segment (the P1 domain) close to the C terminus of the protein. This domain (residues 518-580 in the murine RHAMMv4 isoform) has been expressed and shown to be functionally active, and its solution structure has been determined (48).2,3 As shown in Fig. 2, it consists of a helix-loop-helix motif. The P1 domain includes a region of 34 amino acids that has been implicated previously in hyaluronan binding by truncation mutagenesis (49). Two clusters of basic amino acids (531KQKIKHVVKLK541 and 553KLRSQLVKRK562) have been identified within this region, and these have been reported to be involved in mediating the interaction with hyaluronan (46). This led to the suggestion (46) that linear sequences termed BX7B motifs (where B is either lysine or arginine and X can be any amino acid apart from acidic residues) are likely to be a minimal requirement for hyaluronan binding in RHAMM and other hyaladherins. This study involved the expression of short basic peptides (and related mutants) fused onto the C terminus of residues 1-238 of RHAMM followed by determination of hyaluronan binding activity using a transblot assay. However, this experimental approach should be viewed with caution because the pendant BX7B peptides were not displayed in the normal context of the hyaluronan-binding domain and likely lacked important contributions from secondary and tertiary structure. Although Arg-46 of CD44 (which is part of a BX7B motif) was identified as important for hyaluronan binding in these experiments, subsequent work has indicated that it is not involved in the interaction (44, 50). The recent determination of the structure of the P1 domain will provide the basis for a program of site-directed mutagenesis to define the position of the hyaluronan-binding surface in RHAMM.
BX7B-like sequences are present in I
I (22),
SPACR (27), SPACRCAN (29), CD38 (23), CDC37 (31), P-32 (34), and IHABP4
(37). However, there are no data to indicate that they mediate
hyaluronan binding in these proteins. This spacing of basic amino acids
is extremely common in protein sequences with over 16,000 matches in
the NRL-3D data base alone (i.e. proteins of known tertiary
structure). If X is any amino acid apart from acidic
residues, there are still over 10,000 matches. Therefore, the presence
of a BX7B motif should not be interpreted as an
indicator that a protein will bind hyaluronan nor should it be assumed
that this is necessarily the site of hyaluronan binding activity in a
known hyaladherin.
| |
Toward Understanding the Molecular Basis of Hyaluronan-Protein Interactions |
|---|
|
|
|---|
Basic amino acids have long been presumed to be major determinants in hyaluronan binding by aggrecan and link protein, making ionic bonds with the carboxylic acid group of glucuronic acid (see references in Ref. 38). This is also likely to be the case for CD44 where two arginines (Arg-41 and Arg-78) along with two tyrosines (Tyr-42 and Tyr-79) play a critical role in the interaction with hyaluronan (39, 44). In addition to these four essential residues (dark blue on Fig. 3), other, less critical amino acids (including three lysines, four arginines, two asparagines, and a tyrosine) have also been implicated. The number of residues of CD44 engaged in binding indicates that there is a large network of interactions (distinct for this protein) that maintains the association with hyaluronan. The energetics are clearly finely balanced because the loss of a single hydrogen bond or ionic interaction can be enough to diminish binding significantly (44).
The thermodynamics of hyaluronan-protein binding have been determined for the TSG-6 Link module, where the major energetic contribution driving the interaction is the enthalpy, which is large and exothermic (38). The small change in heat capacity seen on binding is consistent with an intermolecular interface comprising a significant polar or charged component rather than the burial of a large hydrophobic surface area. The interaction of the TSG-6 Link module with HA8 is highly salt strength-dependent. However, ionic interactions may only contribute about 25% of the free energy of binding at physiological sodium ion concentrations (51). Therefore, although it is clear that ionic associations are important, non-ionic interactions (e.g. hydrogen bonding and van der Waals) also contribute significantly to the binding energy. This is consistent with data from site-directed mutagenesis showing that in addition to a lysine, 3 tyrosines and a phenylalanine have a critical role in binding (45).
The crystal structure has been determined for a hyaluronan lyase (from Streptococcus pneumoniae) in complex with two hyaluronan disaccharides in the substrate binding cleft (52). There is an extensive network of hydrogen bonds and electrostatic interactions stabilizing the binding. In addition, sugar rings are seen to stack against aromatic side chains, which is a common feature in protein-carbohydrate complexes.
At present there are few data on the conformations adopted by
hyaluronan after binding to proteins (53). In solution, hyaluronan is
likely to be highly dynamic in nature, adopting a large number of low
energy states (53-55). It is possible that different hyaladherins could capture (and stabilize) distinct transient conformations of
hyaluronan, i.e. the structure of hyaluronan will be
different depending on which protein it associates with (53). A
consequence of this could be that particular hyaladherins are able to
modulate the binding of other proteins by altering the conformation of hyaluronan. However, further structural information on
protein-hyaluronan complexes is necessary for definitive answers.
| |
Regulation of Hyaluronan-Protein Interactions |
|---|
|
|
|---|
A unique feature of the interaction of TSG-6 with hyaluronan is that it is highly pH-dependent, which may serve to regulate the function of this protein in certain tissues (56). There is maximal binding at pH 6 and a dramatic reduction in binding as the pH is increased but with no alteration in the Link module fold. A likely explanation is that raising the pH changes the charge state on a histidine side chain, leading to the loss of a critical interaction (51).
CD44 is present on many cell types (e.g. lymphocytes) in a non-functional form that requires activation to acquire ligand binding activity, unlike most hyaladherins that interact constitutively with hyaluronan. Understanding how the hyaluronan binding function of CD44 is regulated has been a major focus of recent research. This complex issue involves the cell background on which CD44 is expressed, post-translational modifications (including N-glycosylation, GAG attachment, and tyrosine sulfation), the splice isoform involved, membrane composition, phosphorylation of the intracytoplasmic domain, cytoskeletal attachment, molecular clustering, and receptor density on the cell surface (10, 43, 57-59). A detailed discussion of each of these is clearly outside the scope of this review, and here we will focus just on N-glycosylation.
The hyaluronan-binding domain of human CD44 contains six potential sites for N-linked carbohydrate attachment, and expression of this region in Escherichia coli indicates that glycosylation is not obligatory at any of these sites for either correct folding or functional activity (40). This conclusion is consistent with results from one study (60) but at odds with another (61). Although glycosylation is unlikely to be required for hyaluronan binding, it is clearly one of the principal mechanisms modulating the interaction between CD44 and hyaluronan (11), and there is differential glycosylation of the receptor depending on cell type and cell activation state. Removal of N-glycans by the mutation of the first or fifth glycosylation sites, which are on the N- and C-terminal extensions, respectively, can switch CD44 in an "inducible" cell background into a constitutively active form (60). However, the presence of N-linked carbohydrate at all positions on a "constitutive" cell line does not inhibit binding. This may be because of particular carbohydrate structures at sites 1 and 5 causing steric interference by blocking hyaluronan binding; alternatively, certain N-glycans may prevent receptor clustering or fix the protein in a non-binding conformation.
The activation of cells to become hyaluronan binding by changes in the CD44 glycoform present on their surface (i.e. by de novo synthesis) would be relatively slow. Rapid induction in vivo (e.g. on leukocytes) may occur by the removal of sialic acid (potentially by an endogenous sialidase) as this has been shown to be a major up-regulator of hyaluronan binding function in CD44 (60, 62, 63).
The molecular basis of CD44 regulation should become clearer once the
tertiary structure of the hyaluronan-binding domain is known, as this
will reveal the positions of the glycosylation sites relative to the
ligand interaction surface.
| |
Summary |
|---|
|
|
|---|
In recent years significant advances have been made in the
identification of new hyaladherins and in our knowledge of
hyaluronan-protein interactions. Determination of the three-dimensional
structures of different types of hyaluronan-binding domains and their
ligand complexes is clearly essential if we are to understand the
molecular mechanisms underlying the diverse biology of this important glycosaminoglycan.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Michael Ziebell for unpublished data and Eva Turley for informative discussions.
| |
FOOTNOTES |
|---|
* This minireview will be reprinted in the 2002 Minireview Compendium, which will be available in December, 2002. Financial support was provided by the Medical Research Council and Arthritis Research Campaign (to A. J. D.) and by the University of Utah and United States Department of Defense Grant DAMD 17-98-1-8254 (to G. D. P.).
§ To whom correspondence should be addressed: MRC Immunochemistry Unit, Dept. of Biochemistry, South Parks Rd., University of Oxford, Oxford OX1 3QU, UK. Tel.: 44-1865-275349; Fax: 44-1865-275729; E-mail: ajday@bioch.ox.ac.uk.
Published, JBC Papers in Press, November 20, 2001, DOI 10.1074/jbc.R100036200
2 M. R. Ziebell and G. D. Prestwich, unpublished data.
3 M. R. Ziebell, Z. Zhao, B. Luo, L. Luo, E. A. Turley, and G. D. Prestwich, unpublished data.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
GAG, glycosaminoglycan;
RHAMM, receptor for hyaluronan-mediated motility;
TSG-6, tumor necrosis factor-stimulated gene-6;
I
I, inter-
-inhibitor.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Tammi, M. I.,
Day, A. J.,
and Turley, E. A.
(2002)
J. Biol. Chem.
277,
4581-4584 |
| 2. |
Turley, E. A.,
Noble, P. W.,
and Bourguignon, L. Y. W.
(2002)
J. Biol. Chem.
277,
4589-4592 |
| 3. |
Toole, B. P.,
Wight, T. N.,
and Tammi, M. I.
(2002)
J. Biol. Chem.
277,
4593-4596 |
| 4. | Day, A. J. (1999) Biochem. Soc. Trans. 27, 115-121[Medline] [Order article via Infotrieve] |
| 5. | Kohda, D., Morton, C. J., Parkar, A. A., Hatanaka, H., Inagaki, F. M., Campbell, I. D., and Day, A. J. (1996) Cell 86, 767-775[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Watanabe, H.,
Cheung, S. C.,
Itano, N.,
Kimata, K.,
and Yamada, Y.
(1997)
J. Biol. Chem.
272,
28057-28065 |
| 7. | Yamaguchi, Y. (2000) Cell. Mol. Life Sci. 57, 276-289[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Hirakawa, S., Oohashi, T., Su, W. D., Yoshioka, H., Murakami, T., Arata, J., and Ninomiya, Y. (2000) Biochem. Biophys. Res. Commun. 276, 982-989[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Lee, J. Y., and Spicer, A. P. (2000) Curr. Opin. Cell Biol. 12, 581-586[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Goodison, S., Urquidi, V., and Tarin, D. (1999) J. Clin. Pathol. Mol. Pathol. 52, 189-196[Abstract] |
| 11. | Lesley, J., Hyman, R., English, N., Catterall, J. B., and Turner, G. A. (1997) Glycoconj. J. 14, 611-622[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Prevo, R.,
Banerji, S.,
Ferguson, D. J.,
Clasper, S.,
and Jackson, D. G.
(2001)
J. Biol. Chem.
276,
19420-19430 |
| 13. | Wisniewski, H. G., and Vilcek, J. (1997) Cytokine Growth Factor Rev. 8, 143-156[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Bayliss, M. T., Howat, S. L., Dudhia, J., Murphy, J. M., Barry, F. P., Edwards, J. C., and Day, A. J. (2001) Osteoarthritis Cartilage 9, 42-48[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Nagase, T., Seki, N., Ishikawa, K., Ohira, M., Kawarabayasi, Y., Ohara, O., Tanaka, A., Kotani, H., Miyajima, N., and Nomura, N. (1996) DNA Res. 3, 321-329[Abstract] |
| 16. |
Tsifrina, E.,
Ananyeva, N. M.,
Hastings, G.,
and Liau, G.
(1999)
Am. J. Pathol.
155,
1625-1633 |
| 17. | Nagase, T., Ishikawa, K., Miyajima, N., Tanaka, A., Kotani, H., Nomura, N., and Ohara, O. (1998) DNA Res. 5, 31-39[Abstract] |
| 18. | Bost, F., Diarra-Mehrpour, M., and Martin, J. P. (1998) Eur. J. Biochem. 252, 339-346[Medline] [Order article via Infotrieve] |
| 19. | Enghild, J. J., Thogersen, I. B., Cheng, F., Fransson, L. A., Roepstorff, P., and Rahbek-Nielsen, H. (1999) Biochemistry 38, 11804-11813[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Zhao, M.,
Yoneda, M.,
Ohashi, Y.,
Kurono, S.,
Iwata, H.,
Ohnuki, Y.,
and Kimata, K.
(1995)
J. Biol. Chem.
270,
26657-26663 |
| 21. |
Hess, K. A.,
Chen, L.,
and Larsen, W. J.
(1999)
Biol. Reprod.
61,
436-443 |
| 22. |
Chen, L.,
Mao, S. J.,
McLean, L. R.,
Powers, R. W.,
and Larsen, W. J.
(1994)
J. Biol. Chem.
269,
28282-28287 |
| 23. | Nishina, H., Inageda, K., Takahashi, K., Hoshino, S., Ikeda, K., and Katada, T. (1994) Biochem. Biophys. Res. Commun. 203, 1318-1323[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Ferrero, E., and Malavasi, F. (1999) J. Leukocyte Biol. 65, 151-161[Abstract] |
| 25. |
Choi-Miura, N. H.,
Tobe, T.,
Sumiya, J.,
Nakano, Y.,
Sano, Y.,
Mazda, T.,
and Tomita, M.
(1996)
J. Biochem. (Tokyo)
119,
1157-1165 |
| 26. |
Vostrov, A. A.,
and Quitschke, W. W.
(2000)
J. Biol. Chem.
275,
22978-22985 |
| 27. |
Acharya, S.,
Rodriguez, I. R.,
Moreira, E. F.,
Midura, R. J.,
Misono, K.,
Todres, E.,
and Hollyfield, J. G.
(1998)
J. Biol. Chem.
273,
31599-31606 |
| 28. | Kuehn, M. H., and Hageman, G. S. (1999) Matrix Biol. 18, 509-518[CrossRef][Medline] [Order article via Infotrieve] |
| 29. |
Acharya, S.,
Foletta, V. C.,
Lee, J. W.,
Rayborn, M. E.,
Rodriguez, I. R.,
Young, W. S., III,
and Hollyfield, J. G.
(2000)
J. Biol. Chem.
275,
6945-6955 |
| 30. | Bork, P., and Patthy, L. (1995) Protein Sci. 4, 1421-1425[Abstract] |
| 31. |
Grammatikakis, N.,
Grammatikakis, A.,
Yoneda, M., Yu, Q.,
Banerjee, S. D.,
and Toole, B. P.
(1995)
J. Biol. Chem.
270,
16198-16205 |
| 32. | Perdew, G. H., Wiegand, H., Vanden Heuvel, J. P., Mitchell, C., and Singh, S. S. (1997) Biochemistry 36, 3600-3607[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Krainer, A. R., Mayeda, A., Kozak, D., and Binns, G. (1991) Cell 66, 383-394[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Deb, T. B.,
and Datta, K.
(1996)
J. Biol. Chem.
271,
2206-2212 |
| 35. | Rao, C. M., Deb, T. B., Gupta, S., and Datta, K. (1997) Biochim. Biophys. Acta 1336, 387-393[Medline] [Order article via Infotrieve] |
| 36. |
Jiang, J.,
Zhang, Y.,
Krainer, A. R.,
and Xu, R. M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3572-3577 |
| 37. |
Huang, L.,
Grammatikakis, N.,
Yoneda, M.,
Banerjee, S. D.,
and Toole, B. P.
(2000)
J. Biol. Chem.
275,
29829-29839 |
| 38. | Kahmann, J. D., O'Brien, R., Werner, J. M., Heinegard, D., Ladbury, J. E., Campbell, I. D., and Day, A. J. (2000) Structure 8, 763-774[Medline] [Order article via Infotrieve] |
| 39. |
Peach, R. J.,
Hollenbaugh, D.,
Stamenkovic, I.,
and Aruffo, A.
(1993)
J. Cell Biol.
122,
257-264 |
| 40. | Banerji, S., Day, A. J., Kahmann, J. D., and Jackson, D. G. (1998) Protein Expression Purif. 14, 371-381[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Grover, J., and Roughley, P. J. (1994) Biochem. J. 300, 317-324 |
| 42. |
Tammi, R.,
MacCallum, D.,
Hascall, V. C.,
Pienimäki, J. P.,
Hyttinen, M.,
and Tammi, M.
(1998)
J. Biol. Chem.
273,
28878-28888 |
| 43. |
Lesley, J.,
Hascall, V. C.,
Tammi, M.,
and Hyman, R.
(2000)
J. Biol. Chem.
275,
26967-26975 |
| 44. |
Bajorath, J.,
Greenfield, B.,
Munro, S. B.,
Day, A. J.,
and Aruffo, A.
(1998)
J. Biol. Chem.
273,
338-343 |
| 45. |
Mahoney, D. J.,
Blundell, C. D.,
and Day, A. J.
(2001)
J. Biol. Chem.
276,
22764-22771 |
| 46. | Yang, B., Yang, B. L., Savani, R. C., and Turley, E. A. (1994) EMBO J. 13, 286-296[Medline] [Order article via Infotrieve] |
| 47. | Parkar, A. A., and Day, A. J. (1997) FEBS Lett. 410, 413-417[CrossRef][Medline] [Order article via Infotrieve] |
| 48. | Ziebell, M. R. (2000) Ligand Binding and Structural Characterization of a Recombinant Hyaluronic Acid Ligand Binding Domain. Ph.D. dissertation , State University of New York, Stony Brook, NY |
| 49. |
Yang, B.,
Zhang, L.,
and Turley, E. A.
(1993)
J. Biol. Chem.
268,
8617-8623 |
| 50. |
Telen, M. J.,
Udani, M.,
Washington, M. K.,
Levesque, M. C.,
Lloyd, E.,
and Rao, N.
(1996)
J. Biol. Chem.
271,
7147-7153 |
| 51. | Blundell, C. D., Kahmann, J. D., Perczel, A., Mahoney, D. J., Cordell, M. R., Teriete, P., Campbell, I. D., and Day, A. J. (2002) in Hyaluronan 2000 (Kennedy, J. F., ed) , Woodhead Publishing Ltd., Abington, Cambridge, in press |
| 52. | Ponnuraj, K., and Jedrzejas, M. J. (2000) J. Mol. Biol. 299, 885-895[CrossRef][Medline] [Order article via Infotrieve] |
| 53. | Day, A. J., and Sheehan, J. K. (2001) Curr. Opin. Struct. Biol. 11, 617-622[CrossRef][Medline] [Order article via Infotrieve] |
| 54. | Almond, A., Brass, A., and Sheehan, J. K. (1998) J. Mol. Biol. 284, 1425-1437[CrossRef][Medline] [Order article via Infotrieve] |
| 55. | Almond, D., Brass, A., and Sheehan, J. K. (2000) J. Phys. Chem. B 104, 5634-5640[CrossRef] |
| 56. | Parkar, A. A., Kahmann, J. D., Howat, S. L. T., Bayliss, M. T., and Day, A. J. (1998) FEBS Lett. 428, 171-176[CrossRef][Medline] [Order article via Infotrieve] |
| 57. |
Bourguignon, L. Y.,
Zhu, H.,
Shao, L.,
and Chen, Y. W.
(2000)
J. Biol. Chem.
275,
1829-1838 |
| 58. | Lesley, J., English, N., Charles, C., and Hyman, R. (2000) Eur. J. Immunol. 30, 245-253[CrossRef][Medline] [Order article via Infotrieve] |
| 59. |
Oliferenko, S.,
Kaverina, I.,
Small, J. V.,
and Huber, L. A.
(2000)
J. Cell Biol.
148,
1159-1164 |
| 60. |
English, N. M.,
Lesley, J. F.,
and Hyman, R.
(1998)
Cancer Res.
58,
3736-3742 |
| 61. |
Bartolazzi, A.,
Nocks, A.,
Aruffo, A.,
Spring, F.,
and Stamenkovic, I.
(1996)
J. Cell Biol.
132,
1199-1208 |
| 62. |
Skelton, T. P.,
Zeng, C.,
Nocks, A.,
and Stamenkovic, I.
(1998)
J. Cell Biol.
140,
431-446 |
| 63. |
Katoh, S.,
Miyagi, T.,
Taniguchi, H.,
Matsubara, Y.,
Kadota, J.,
Tominaga, A.,
Kincade, P. W.,
Matsukura, S.,
and Kohno, S.
(1999)
J. Immunol.
162,
5058-5061 |
This article has been cited by other articles:
![]() |
E. N. Harris and P. H. Weigel The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates A, C, and D bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and CS-E Glycobiology, August 1, 2008; 18(8): 638 - 648. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Kyosseva, E. N. Harris, and P. H. Weigel The Hyaluronan Receptor for Endocytosis Mediates Hyaluronan-dependent Signal Transduction via Extracellular Signal-regulated Kinases J. Biol. Chem., May 30, 2008; 283(22): 15047 - 15055. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Maxwell, J. McCarthy, and E. Turley Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J. Cell Sci., April 1, 2008; 121(7): 925 - 932. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hemming, D. C. Martin, E. Slominski, J. I. Nagy, A. J. Halayko, S. Pind, and B. Triggs-Raine Mouse Hyal3 encodes a 45- to 56-kDa glycoprotein whose overexpression increases hyaluronidase 1 activity in cultured cells Glycobiology, April 1, 2008; 18(4): 280 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kastner, G. J. Thomas, R. H. Jenkins, M. Davies, and R. Steadman Hyaluronan Induces the Selective Accumulation of Matrix- and Cell-Associated Proteoglycans by Mesangial Cells Am. J. Pathol., December 1, 2007; 171(6): 1811 - 1821. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Johnson, R. Prevo, S. Clasper, and D. G. Jackson Inflammation-induced Uptake and Degradation of the Lymphatic Endothelial Hyaluronan Receptor LYVE-1 J. Biol. Chem., November 16, 2007; 282(46): 33671 - 33680. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Blundell, D. J. Mahoney, M. R. Cordell, A. Almond, J. D. Kahmann, A. Perczel, J. D. Taylor, I. D. Campbell, and A. J. Day Determining the Molecular Basis for the pH-dependent Interaction between the Link Module of Human TSG-6 and Hyaluronan J. Biol. Chem., April 27, 2007; 282(17): 12976 - 12988. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Wang, L. A. Garza, S. Kang, J. Varani, J. S. Orringer, G. J. Fisher, and J. J. Voorhees In Vivo Stimulation of De Novo Collagen Production Caused by Cross-linked Hyaluronic Acid Dermal Filler Injections in Photodamaged Human Skin Arch Dermatol, February 1, 2007; 143(2): 155 - 163. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. Gale, R. Prevo, J. Espinosa, D. J. Ferguson, M. G. Dominguez, G. D. Yancopoulos, G. Thurston, and D. G. Jackson Normal Lymphatic Development and Function in Mice Deficient for the Lymphatic Hyaluronan Receptor LYVE-1 Mol. Cell. Biol., January 15, 2007; 27(2): 595 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. M. Nolte-'t Hoen, C. R. Almeida, N. R. Cohen, S. Nedvetzki, H. Yarwood, and D. M. Davis Increased surveillance of cells in mitosis by human NK cells suggests a novel strategy for limiting tumor growth and viral replication Blood, January 15, 2007; 109(2): 670 - 673. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takeda, S. Ogino, R. Umemoto, M. Sakakura, M. Kajiwara, K. N. Sugahara, H. Hayasaka, M. Miyasaka, H. Terasawa, and I. Shimada Ligand-induced Structural Changes of the CD44 Hyaluronan-binding Domain Revealed by NMR J. Biol. Chem., December 29, 2006; 281(52): 40089 - 40095. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Zhang, P. Hopwood, C. C. Abrams, A. Downing, F. Murray, R. Talbot, A. Archibald, S. Lowden, and L. K. Dixon Macrophage Transcriptional Responses following In Vitro Infection with a Highly Virulent African Swine Fever Virus Isolate. J. Virol., November 1, 2006; 80(21): 10514 - 10521. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Kuznetsova, P. Issa, E. M. Perruccio, B. Zeng, J. M. Sipes, Y. Ward, N. T. Seyfried, H. L. Fielder, A. J. Day, T. N. Wight, et al. Versican-thrombospondin-1 binding in vitro and colocalization in microfibrils induced by inflammation on vascular smooth muscle cells J. Cell Sci., November 1, 2006; 119(21): 4499 - 4509. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhuo, A. Kanamori, R. Kannagi, N. Itano, J. Wu, M. Hamaguchi, N. Ishiguro, and K. Kimata SHAP Potentiates the CD44-mediated Leukocyte Adhesion to the Hyaluronan Substratum J. Biol. Chem., July 21, 2006; 281(29): 20303 - 20314. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Deepa, D. Carulli, C. Galtrey, K. Rhodes, J. Fukuda, T. Mikami, K. Sugahara, and J. W. Fawcett Composition of Perineuronal Net Extracellular Matrix in Rat Brain: A DIFFERENT DISACCHARIDE COMPOSITION FOR THE NET-ASSOCIATED PROTEOGLYCANS J. Biol. Chem., June 30, 2006; 281(26): 17789 - 17800. [Abstract] [Full Text] [PDF] |
||||
![]() |